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Background: According to the World Health Organization position
paper, immunodeficiency such as human immunodeficiency virus
(HIV) infection is a relative contraindication for specific immuno-
therapy (SIT). Since the introduction of highly active antiretroviral
therapy, a significant reconstitution of immune competence in indi-
viduals with HIV is possible.
Case Report: In a 52-year-old man, HIV infection was diagnosed in
1987. Antiretroviral therapy was started in 1998. He presented
himself in July 2001 because of an increasingly severe seasonal
rhinoconjunctivitis. Symptoms were not sufficiently alleviated by
various antiallergic drugs.
Results: The investigations showed a relevant sensitization to tree
pollens. Specific immunotherapy with a tree pollen mix (hazel, birch,
ash, and alder, 25% each) was started in November 2001. Viral load at
this time was less than 50 copies/mL, the CD4 cell count was 307/L.
Therapy was given in monthly intervals until mid-April 2005 without
any side effects. Viral load and CD4 cell counts did not change during
SIT. Clinically, rhinoconjunctivitis was experienced only intermittently
and symptom relief was almost 90%.
Conclusions: This report indicates that in patients with well-con-
trolled HIV infection on highly active antiretroviral therapy, SIT
with pollen extracts is a potential and successful therapeutic option.
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The incidence of atopy and respiratory allergies to commoninhalants in human immunodeficiency virus (HIV)–in-
fected patients is similar as in the general population.1 Al-
though pollen allergy with classical rhinoconjunctivitis is not
a life-threatening disease, symptoms may severely affect an
individual and impair his quality of life. Therapeutic ap-
proaches are avoidance, symptomatic medications, and spe-
cific immunotherapy (SIT) with certain allergens. Often,
symptomatic treatment with oral antihistamines, mast cell
stabilizers, and topical corticosteroids is not sufficient to
suppress clinical symptoms, and thus, allergen SIT is a
potential and established option to treat inhalant allergy.
Guidelines and position papers may help in the decision
making of a management. According to the World Health
Organization recommendation on allergen immunotherapy,
immunodeficiency such as HIV is a relative contraindication
for allergen SIT.2 However, principles do not satisfy all
clinical real-life situations. Since the introduction of highly
active antiretroviral therapy (HAART),3 a significant recon-
stitution of immune competence in individuals with HIV is
possible.4,5
In this case report, we aim to consider SIT as a real and
potential therapeutic option in HIV-positive patients if anti-
retroviral therapy is well established and HIV infection is
controlled.
CASE REPORTS
In a 52-year-old white man, HIV infection was diagnosed in
1987, and HAART was started in 1998 when the CD4 cell count,
measured by flow cytometry, was 179/L, and the viral load was
142,412 HIV RNA copies/mL (AMPLICOR HIV-1 Monitor Test,
v1.5, Roche Diagnostics, Rotkreuz, Switzerland).
He presented himself at the allergy outpatient clinic in July
2001 because he increasingly experienced a severe seasonal rhino-
conjunctivitis since 1997. Symptoms were not sufficiently alleviated
by various antiallergic drugs.
The investigations with skin prick tests including common
aeroallergens (ALK-Abello, Horsholm, Denmark) showed relevant
sensitizations to tree pollens (hazel, alder, birch, and ash). Specific
immunoglobulin E (IgE) to rBet v 1 was elevated with 25.2 kU/L
(class 4).
Before the initiation of immunotherapy, the patient has been
fully informed about the potential risks and the lack of knowledge
on safety and efficacy of immunotherapy in patients with HIV
infection. Viral load was less than 50 copies/mL and the CD4 cell
count was 307/L before the subcutaneous SIT with hazel, birch,
ash, and alder, 25% each, Alutard SQ (ALK, Denmark), was started
in November 2001 using a cluster regimen.
Pretreatment was done with the antihistamine fexofenadine
180 mg 1 hour before injection. The up-dosing phase until reaching
the maintenance dose of 100,000 SQ-U was uneventful. Maintenance
dose was given in monthly intervals until mid-April 2005 without any
side effects except local swellings at the injection site. During therapy,
CD4 cell count increased and remained greater than 350 cells/L,
HIV RNA level was always less than 50 copies/mL. Specific and
total IgE decreased under therapy (Table 1). Clinically, after 3 years
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of immunotherapy, seasonal rhinoconjunctivitis was experienced
only intermittently. No additional medications were used. The over-
all symptom relief determined by history, visual analogue scale for
subjective symptoms, and medication use was almost 90%. Today,
3 years after discontinuation of immunotherapy, typical clinical
symptoms of pollen allergy did not reoccur, and no antiallergic
medications were needed during the last 3 pollen seasons. The HIV
infection is still well controlled under HAART.
In summary, HIV-infected patients may experience relevant
IgE-mediated respiratory diseases that need more than only symp-
tomatic treatment. This report indicates that in patients with well-
controlled HIV infection on antiretroviral therapy, SIT with pollen
extracts is a potential and successful therapeutic option. Specific
immunotherapy still may be considered as a relative contraindica-
tion in untreated HIV-positive patients but should probably be
offered more frequently to HIV-infected patients on successful
antiretroviral therapy.
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TABLE 1. Development of CD4 Cell Count, HIV RNA










April 2001 510 50 25.2(4) 232
April 2002 536 50 15.7(3)
July 2003 521 50 12.9(3)
July 2004 660 50 15.3(3)
May 2005 579 50 10.2(3) 37.3
June 2008 559 50 13.5(3) 70.1
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